Braveheart Bio (NASDAQ:BRVE) Stock Price & Analysis

–

USD

–(–)

Company Profile

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

CEOTravis Murdoch

SectorHealthcare

IndustryBiotechnology

Employees30

IPO DateAug 6, 2026

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

AddressOne Letterman Drive, Building A, Suite A4-300

City / State / ZIPSan Francisco, CA, 94129

CountryUnited States

Websitehttp://www.braveheart.bio

Braveheart Bio, Inc.

Company Profile

Recently from Cashu